» Articles » PMID: 31720897

Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder

Overview
Journal AAPS J
Specialty Pharmacology
Date 2019 Nov 14
PMID 31720897
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: In this paper, we studied the effect over time of agomelatine, an antidepressant drug administered in patient with major depressive disorder, through item response theory (IRT), taking into account a strong placebo effect and missing not at random. We also assessed the informativeness of the HAMD-17 scale's item.

Materials And Methods: The data includes five phase III clinical trials sponsored by Servier Institute, totalling 1549 patients followed during a maximum of 1 year. At each observation, individual scores for the 17 items of the HAMD scale were recorded. The probability for each score was modelled with IRT. A non-linear mixed effects model was used to describe the evolution of the disease and was coupled with a time to event model to predict dropout. Clinical trial simulations were then used to compare placebo and active treatment. Informativeness of each item was evaluated using the Fisher information theory.

Results: The best model combined an IRT model, a longitudinal model for underlying depression which describes the remission and then a possible relapse, and a hazard model for dropout depending on the evolution from baseline. The drug effect was best modelled as an effect on the remission and the relapse phases. The median predicted drop in HAMD between baseline and 6 weeks was 8.8 (90% PI, 8.3-9.2) when on placebo and 13.1 (90% PI, 12.8-13.4) when treated. Nine items were found to be the most informative.

Conclusion: The IRT framework allowed to characterise the evolution of depression with time and estimate the effect of agomelatine, as well as the link between symptoms and disease.

Citing Articles

The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making.

Starling M, Kehoe L, Burnett B, Green P, Venkatakrishnan K, Madabushi R Clin Pharmacol Ther. 2024; 117(2):343-352.

PMID: 39410710 PMC: 11739755. DOI: 10.1002/cpt.3467.


Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models.

Arrington L, Karlsson M AAPS J. 2024; 26(1):21.

PMID: 38273096 DOI: 10.1208/s12248-023-00883-6.


Item response theory in early phase clinical trials: Utilization of a reference model to analyze the Montgomery-Åsberg Depression Rating Scale.

Otto M, Bergmann K, de Kam M, Recourt K, Jacobs G, van Esdonk M CPT Pharmacometrics Syst Pharmacol. 2023; 12(10):1425-1436.

PMID: 37551774 PMC: 10583236. DOI: 10.1002/psp4.13018.

References
1.
Valitalo P, Krekels E, van Dijk M, Simons S, Tibboel D, Knibbe C . Morphine Pharmacodynamics in Mechanically Ventilated Preterm Neonates Undergoing Endotracheal Suctioning. CPT Pharmacometrics Syst Pharmacol. 2017; 6(4):239-248. PMC: 5397563. DOI: 10.1002/psp4.12156. View

2.
Racagni G, Riva M, Molteni R, Musazzi L, Calabrese F, Popoli M . Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry. 2011; 12(8):574-87. DOI: 10.3109/15622975.2011.595823. View

3.
Verma N, Beretvas S, Pascual B, Masdeu J, Markey M . New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimers Res Ther. 2015; 7(1):64. PMC: 4642693. DOI: 10.1186/s13195-015-0151-0. View

4.
Schneider L, Kennedy R, Wang G, Cutter G . Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology. 2015; 84(11):1121-7. PMC: 4371405. DOI: 10.1212/WNL.0000000000001376. View

5.
Buatois S, Retout S, Frey N, Ueckert S . Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients. Pharm Res. 2017; 34(10):2109-2118. DOI: 10.1007/s11095-017-2216-1. View